MacroGenics Resumes LINNET Study After FDA Lifts Partial Hold on Lorigerlimab?Study MacroGenics, Inc. (MGNX), announced that the FDA has lifted the partial hold on its Phase 2 LINNET study of Lorigerlimab in ovarian cancer and clear cell gynaecologic cancer. Enrollment will resume under a revised protocol with added safety measures, and the company expects a program update by mid-2026. MGNX closed Thursday's trading (April 9, 2026) at $3.44, down 0.29%. Adagio Medical Gains IDE Approval to Expand FULCRUM-VT ...